UK unions lambast plan for major layoffs at MHRA as Brexit takes its toll
The UK’s MHRA may have to lay off about 300 of its 1,200 employees, thanks to a decline in income due to reduced medical product submissions following Brexit, spurring anger among unions across the island.
Five UK unions are now demanding action from Prime Minister Boris Johnson and his government, noting that the layoffs will likely either lead to longer timelines for new drug and device submissions or “the MHRA will be reduced to effectively ‘rubber stamping’ EU regulatory decisions.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.